secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105002
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept
---------------------------------------------------------------------------

- Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.
- Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.
- R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.
- Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.
- Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/0000950170-25-105002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/dnth-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer